Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
5 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Investigating Helium Bubble Nucleation and Growth through Simultaneous In-Situ Cryogenic, Ion Implantation, and Environmental Transmission Electron Microscopy.
Materials (Basel). 2019 Aug 16;12(16):2618. doi: 10.3390/ma12162618.
Materials (Basel). 2019.
PMID: 31426387
Free PMC article.
Enhanced Radiation Tolerance of Tungsten Nanoparticles to He Ion Irradiation.
Aradi E, Lewis-Fell J, Harrison RW, Greaves G, Mir AH, Donnelly SE, Hinks JA.
Aradi E, et al.
Nanomaterials (Basel). 2018 Dec 14;8(12):1052. doi: 10.3390/nano8121052.
Nanomaterials (Basel). 2018.
PMID: 30558254
Free PMC article.
Item in Clipboard
Effect of aluminium concentration on phase formation and radiation stability of Cr2Al x C thin film.
Imtyazuddin M, Mir AH, Aradi E, Vishnyakov V.
Imtyazuddin M, et al. Among authors: aradi e.
Nanotechnology. 2020 Sep 18;31(38):385602. doi: 10.1088/1361-6528/ab991c. Epub 2020 Jun 3.
Nanotechnology. 2020.
PMID: 32492661
Item in Clipboard
TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2.
Khanani AM, Kotecha A, Chang A, Chen SJ, Chen Y, Guymer R, Heier JS, Holz FG, Iida T, Ives JA, Lim JI, Lin H, Michels S, Quezada Ruiz C, Schmidt-Erfurth U, Silverman D, Singh R, Swaminathan B, Willis JR, Tadayoni R; TENAYA and LUCERNE Investigators.
Khanani AM, et al.
Ophthalmology. 2024 Feb 19:S0161-6420(24)00134-9. doi: 10.1016/j.ophtha.2024.02.014. Online ahead of print.
Ophthalmology. 2024.
PMID: 38382813
Free article.
Item in Clipboard
Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.
Heier JS, Khanani AM, Quezada Ruiz C, Basu K, Ferrone PJ, Brittain C, Figueroa MS, Lin H, Holz FG, Patel V, Lai TYY, Silverman D, Regillo C, Swaminathan B, Viola F, Cheung CMG, Wong TY; TENAYA and LUCERNE Investigators.
Heier JS, et al.
Lancet. 2022 Feb 19;399(10326):729-740. doi: 10.1016/S0140-6736(22)00010-1. Epub 2022 Jan 24.
Lancet. 2022.
PMID: 35085502
Clinical Trial.
Item in Clipboard
Cite
Cite